Добавил:

Sekretar kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.

Вуз:

Ростовский Государственный Медицинский Университет

Предмет:

Медицина общая

Файл:

Книга_5397_Библиотеки_им_академика_М_И_Перельмана

.pdf

Скачиваний:

Добавлен:

15.09.2026

Размер:

15 Мб

Скачать

☆

<<< < Предыдущая 16 17 18 19 20 21 22 23 24 25 26 2728 / 4828 29 30 31 32 33 34 35 36 37 38 39 40 > Следующая >>>

12 Immunoinformatics fortheDiagnosis andMonitoring ofAutoimmune Diseases

https://t.me/med1917

Systems Immunology Integration

Immunoinformatics integrates with systems like immunology, providing a thorough understanding of immune responses at the system level. This combination has the potential to identify complex regulatory networks and improve immune prediction (Tong and Ren 2009).

Multi-model Data Fusion

The future of immunoinformatics involves harnessing the power of multi-modal data fusion. By combining data from various sources such as genomics, transcriptomics, and proteomics, researchers can gain a more holistic view of immune system dynamics and responses (Chakraborty etal. 2021).

Enhanced Vaccine Design Strategies

Immunoinformatics will rene vaccine design strategies in the future, with a focus on producing vaccinations against difcult infections. This includes aspects such as antigenic variation and the evolution of infectious agents (Prawiningrum etal. 2022).

259

Machine Learning inImmunoinformatics

Machine learning algorithm developments will be critical in enhancing immunoinformatics predictions. Deep learning and neural networks could lead to more precise epitope predictions and comprehensive immune system behaviour studies (Alkaff etal. 2020).

12.7.2 Challenges inImmunoinformatics

Complexity ofAntigen Recognition

An epitope is a complicated structure with numerous interactions going on; understanding the complicated mechanics of antigen recognition is a challenge for immunoinformatics. More advancement is needed to understand the many interactions between immune system components and antigens (Tong and Ren 2009).

260

https://t.me/med1917

Data Integration andStandardization

Immunoinformatics is based on algorithms and data, and integration of nonstandardized immunological data poses a signicant challenge. Standardizing data formats and terminologies is vital for effective collaboration and interpretation of results (Tong and Ren 2009).

Vaccine Safety

Designing effective vaccines demands overcoming challenges such as safety, even though ADME (absorption, distribution, metabolism, excretion) can be analysed virtually with some degree of success, it is still far behind the real-world scenario, which will eventually require invitro and invivo analysis.

S. Gangwar et al.

12.8 Discussion

Autoimmune diseases pose signicant challenges due to their complex aetiology, diverse clinical manifestations, and lack of specic diagnostic markers. Traditional diagnostic approaches often rely on time-consuming and expensive laboratory techniques, hindering the development of personalized treatment strategies. Immunoinformatics, an interdisciplinary eld that integrates immunology, bioinformatics, and computational biology, offers a promising solution to address these challenges by providing powerful tools for analysing immune system data and identifying novel targets for diagnosis and therapy. The development of autoimmune disorder is due to the complex interplay of genetic, environmental, and immunological factors. Regulatory T cells (Tregs) play a crucial role in maintaining immune system balance and preventing autoimmune reactions.

Fundamentals of immunoinformatics focuses on computational analysis of immune receptors, epitope prediction, and vaccine design. The prediction of major histocompatibility complex (MHC)-binding peptides for antigen presentation can be done by utilizing tools like NetMHC and SYFPEITHI.The advancements in high-throughput sequencing technology and the role of deep learning in analysing immune repertoires.

Applications of immunoinformatics range from the identication of biomarkers through the analysis of omics data and offer more specic and sensitive diagnostic tools to peptide microarray-based diagnostics powered by immunoinformatics.

Immunoinformatics is emerging as a transformative approach in the diagnosis and monitoring of autoimmune diseases, offering personalized and efcient solutions through the integration of computational techniques with immunological insights. Ongoing advancements in this eld hold the promise of revolutionizing our understanding and the management of autoimmune disorders in the future.

12 Immunoinformatics fortheDiagnosis andMonitoring ofAutoimmune Diseases

https://t.me/med1917

261

References

Alkaff AH, Saragih M, Fardiansyah MA, Tambunan USF (2020) Role of Immunoinformatics

in accelerating epitope-based vaccine development against dengue virus. Open Biochem

J 14:9–18 Anaya J-M, Ramirez-Santana C, Alzate MA, Molano-Gonzalez N, Rojas-Villarraga A (2016) The

autoimmune ecology. Front Immunol 7:139. https://doi.org/10.3389/mmu.2016.00139 Anderson EM, Goodwin EC, Verma A et al (2021) Seasonal human coronavirus antibod-

ies are boosted upon SARS-CoV-2 infection but not associated with protection. Cell

184:1858–1864.e10 Andreatta M, Nielsen M (2016) Gapped sequence alignment using articial neural networks:

application to the MHC class I system. Bioinformatics 32:511–517 ASCIA (2023) ASCIA Autoimmune diseases Baecher-Allan C (2004) Human CD4+CD25+ regulatory T cells. Semin Immunol 16:89–98 Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL (2002) CD4+CD25+ regulatory T

cells control Leishmania major persistence and immunity. Nature 420:502–507 Binder SR, Genovese MC, Merrill JT, Morris RI, Metzger AL (2005) Computer-assisted pattern

recognition of autoantibody results. Clin Vaccine Immunol 12:1353–1357 Bolotin DA, Poslavsky S, Mitrophanov I, Shugay M, Mamedov IZ, Putintseva EV, Chudakov

DM (2015) MiXCR: software for comprehensive adaptive immunity proling. Nat Methods

12:380–381 Bolotin DA, Poslavsky S, Davydov AN etal (2017) Antigen receptor repertoire proling from

RNA-seq data. Nat Biotechnol 35:908–911 Bowman BN, McAdam PR, Vivona S etal (2011) Improving reverse vaccinology with a machine

learning approach. Vaccine 29:8156–8164 Braun J, Loyal L, Frentsch M etal (2020) SARS-CoV-2-reactive T cells in healthy donors and

patients with COVID-19. Nature 587:270–274 Brusic V, Petrovsky N (2005) Immunoinformatics and its relevance to understanding human

immune disease. Expert Rev Clin Immunol 1:145–157 Chakraborty C, Sharma AR, Bhattacharya M, Sharma G, Lee S-S (2021) Immunoinformatics

approach for the identication and characterization of T cell and B cell epitopes towards the

peptide-based vaccine against SARS-CoV-2. Arch Med Res 52:362–370 Chatanaka MK, Ulndreaj A, Sohaei D, Prassas I (2022) Immunoinformatics: pushing the boundar-

ies of immunology research and medicine. ImmunoInformatics 5:100007 Chemin K, Gerstner C, Malmström V (2019) Effector functions of CD4+ T cells at the site of

local autoimmune inammation—lessons from Rheumatoid Arthritis. Front Immunol 10:353.

https://doi.org/10.3389/mmu.2019.00353

Colson P, Raoult D (2010) Gene repertoire of amoeba-associated Giant viruses. Intervirology

53:330–343 Conrad N, Misra S, Verbakel JY etal (2023) Incidence, prevalence, and co-occurrence of autoim-

mune disorders over time and by age, sex, and socioeconomic status: a population-based cohort

study of 22 million individuals in the UK.Lancet 401:1878–1890 Davis MM, Bjorkman PJ (1988) T-cell antigen receptor genes and T-cell recognition. Nature

334:395–402 Davis MM, Krogsgaard M, Huse M, Huppa J, Lillemeier BF, Li Q (2007) T cells as a self-

referential, sensory organ. Annu Rev Immunol 25:681–695 Day CL, Kaufmann DE, Kiepiela P etal (2006) PD-1 expression on HIV-specic T cells is associ-

ated with T-cell exhaustion and disease progression. Nature 443:350–354 Dendrou CA, Fugger L, Friese MA (2015) Immunopathology of multiple sclerosis. Nat Rev

Immunol 15:545–558 Doytchinova IA, Flower DR (2007) VaxiJen: a server for prediction of protective antigens, tumour

antigens and subunit vaccines. BMC Bioinformatics 8:4

262

https://t.me/med1917

Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, Smith S, Comi G (2004) Interferon

beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple

sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 364:1489–1496 Fujinami RS, Oldstone MBA (1989) Molecular mimicry as a mechanism for virus-induced auto-

immunity. Immunol Res 8:3 Galeotti C, Bayry J (2020) Autoimmune and inammatory diseases following COVID-19. Nat Rev

Rheumatol 16:413–414 Gittelman RM, Lavezzo E, Snyder TM etal (2022) Longitudinal analysis of T cell receptor rep-

ertoires reveals shared patterns of antigen-specic response to SARS-CoV-2 infection. JCI

Insight 7:e151849. https://doi.org/10.1172/jci.insight.151849 Grifoni A, Weiskopf D, Ramirez SI etal (2020) Targets of T cell responses to SARS-CoV-2 corona-

virus in humans with COVID-19 disease and unexposed individuals. Cell 181:1489–1501.e15 He Y, Xiang Z, Mobley HLT (2010) Vaxign: the rst web-based vaccine design program for

reverse vaccinology and applications for vaccine development. J Biomed Biotechnol

2010:1–15 Hirota K, Yoshitomi H, Hashimoto M etal (2007) Preferential recruitment of CCR6-expressing

Th17 cells to inamed joints via CCL20in rheumatoid arthritis and its animal model. J Exp

Med 204:2803–2812 Huang W, Hu C, Zeng H, Li P, Guo L, Zeng X, Liu G, Zhang F, Li Y, Wu L (2012) Novel sys-

temic lupus erythematosus autoantigens identied by human protein microarray technology.

Biochem Biophys Res Commun 418:241–246 Jensen KK, Andreatta M, Marcatili P, Buus S, Greenbaum JA, Yan Z, Sette A, Peters B, Nielsen M

(2018) Improved methods for predicting peptide binding afnity to MHC class II molecules.

Immunology 154:394–406 Jones RB, Ndhlovu LC, Barbour JD etal (2008) Tim-3 expression denes a novel population of

dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp

Med 205:2763–2779 Kanduc D (2020) From anti-SARS-CoV-2 immune responses to COVID-19 via molecular mim-

icry. Antibodies 9:33 Kassu A, Marcus RA, D’Souza MB, Kelly-McKnight EA, Golden-Mason L, Akkina R, Fontenot

AP, Wilson CC, Palmer BE (2010) Regulation of virus-specic CD4+ T cell function by mul-

tiple costimulatory receptors during chronic HIV infection. J Immunol 185:3007–3018 Katayama Y, Yokota R, Akiyama T, Kobayashi TJ (2022) Machine learning approaches to TCR

repertoire analysis. Front Immunol 13:858057. https://doi.org/10.3389/mmu.2022.858057 Kaufmann DE, Kavanagh DG, Pereyra F etal (2007) Upregulation of CTLA-4 by HIV-specic

CD4+ T cells correlates with disease progression and denes a reversible immune dysfunction.

Nat Immunol 8:1246–1254 Knier B, Berthele A, Buck D, Schmidt P, Zimmer C, Mühlau M, Hemmer B, Korn T (2016)

Optical coherence tomography indicates disease activity prior to clinical onset of central ner-

vous system demyelination. Mult Scler J 22:893–900 Lambin P, Rios-Velazquez E, Leijenaar R etal (2012) Radiomics: extracting more information

from medical images using advanced feature analysis. Eur J Cancer 48:441–446 Lan JL, Wu CH (1992) Detection of Mycobacterium tuberculosis antigen in synovial uid of

patients with Rheumatoid Arthritis. Rheumatology 31:615–618 Marino Gammazza A, Légaré S, Lo Bosco G, Fucarino A, Angileri F, Conway de Macario E,

Macario AJ, Cappello F (2020) Human molecular chaperones share with SARS-CoV-2 anti-

genic epitopes potentially capable of eliciting autoimmunity against endothelial cells: possible

role of molecular mimicry in COVID-19. Cell Stress Chaperones 25:737–741 Mathew S, Fakhroo AD, Smatti M, Al Thani AA, Yassine HM (2022) Immunoinformatics predic-

tion of potential immunodominant epitopes from human coronaviruses and association with

autoimmunity. Immunogenetics 74:213–229 Mayerhoefer ME, Materka A, Langs G, Häggström I, Szczypiński P, Gibbs P, Cook G (2020)

Introduction to radiomics. J Nucl Med 61:488–495

S. Gangwar et al.

12 Immunoinformatics fortheDiagnosis andMonitoring ofAutoimmune Diseases

https://t.me/med1917

Mose LE, Selitsky SR, Bixby LM, Marron DL, Iglesia MD, Serody JS, Perou CM, Vincent BG,

Parker JS (2016) Assembly-based inference of B-cell receptor repertoires from short read RNA

sequencing data with V’DJer. Bioinformatics 32:3729–3734 Nicholson LB (2016) The immune system. Essays Biochem 60:275–301 NIEHS (n.d.) Autoimmune Diseases. Natl Inst Environ Heal Sci Oli AN, Obialor WO, Ifeanyichukwu MO, Odimegwu DC, Okoyeh JN, Emechebe GO,

Adejumo SA, Ibeanu GC (2020) Immunoinformatics and vaccine development: an overview.

Immunotargets Ther 9:13–30 Ott PA, Hu Z, Keskin DB etal (2017) An immunogenic personal neoantigen vaccine for patients

with melanoma. Nature 547:217–221 Palmer BE, Neff CP, LeCureux J, Ehler A, Dsouza M, Remling-Mulder L, Korman AJ, Fontenot

AP, Akkina R (2013) In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and

improves CD4+ T cell levels in humanized mice. J Immunol 190:211–219 Pappalardo F, Russo G, Pennisi M, Parasiliti Palumbo GA, Sgroi G, Motta S, Maimone D (2020)

The potential of computational modeling to predict disease course and treatment response in

patients with relapsing multiple sclerosis. Cell 9:586 Pennisi M, Rajput A-M, Toldo L, Pappalardo F (2013) Agent based modeling of Treg-Teff cross

regulation in relapsing-remitting multiple sclerosis. BMC Bioinformatics 14:S9 Ponomarenko J, Bui H-H, Li W, Fusseder N, Bourne PE, Sette A, Peters B (2008) ElliPro: a new

structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics 9:514 Prawiningrum AF, Paramita RI, Panigoro SS (2022) Immunoinformatics approach for epitope-

based vaccine design: key steps for breast cancer vaccine. Diagnostics 12:2981 Rammensee H-G, Bachmann J, Emmerich NPN, Bachor OA, Stevanović S (1999) SYFPEITHI:

database for MHC ligands and peptide motifs. Immunogenetics 50:213–219 Rappuoli R (2000) Reverse vaccinology. Curr Opin Microbiol 3:445–450 Rashid T, Ebringer A (2007) Rheumatoid arthritis is linked to proteus—the evidence. Clin

Rheumatol 26:1036–1043 Rashid T, Ebringer A, Wilson C (2017) The link between Proteus mirabilis, environmental factors

and autoantibodies in rheumatoid arthritis. Clin Exp Rheumatol 35:865–871 Ren C, Li M, Du W, Lü J, Zheng Y, Xu H, Quan R (2020) Comprehensive bioinformatics analysis

reveals hub genes and inammation state of rheumatoid arthritis. Biomed Res Int 2020:1–13 Repac J, Mandić M, Lunić T, Božić B, Božić Nedeljković B (2021) Mining the capacity of human-

associated microorganisms to trigger rheumatoid arthritis—a systematic immunoinformatics

analysis of T cell epitopes. PLoS One 16:e0253918 Rizwan M, Naz A, Ahmad J, Naz K, Obaid A, Parveen T, Ahsan M, Ali A (2017) VacSol: a high

throughput in silico pipeline to predict potential therapeutic targets in prokaryotic pathogens

using subtractive reverse vaccinology. BMC Bioinformatics 18:106 Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance.

Cell 133:775–787 Scher JU, Abramson SB (2011) The microbiome and rheumatoid arthritis. Nat Rev Rheumatol

7:569–578 Shimauchi T, Kabashima K, Nakashima D, Sugita K, Yamada Y, Hino R, Tokura Y (2007)

Augmented expression of programmed death-1in both neoplastic and non-neoplastic CD4 +

T-cells in adult T-cell leukemia/lymphoma. Int J Cancer 121:2585–2590 Song X, Zhang Y, Zhao L etal (2023) Analyzation of the peripheral blood mononuclear cells

atlas and cell communication of rheumatoid arthritis patients based on single-cell RNA-Seq. J

Immunol Res 2023:1–20 Stubbington MJT, Lönnberg T, Proserpio V, Clare S, Speak AO, Dougan G, Teichmann SA (2016)

T cell fate and clonality inference from single-cell transcriptomes. Nat Methods 13:329–332 Szanya V, Ermann J, Taylor C, Holness C, Fathman CG (2002) The subpopulation of CD4+CD25+

Splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of

CCR7. J Immunol 169:2461–2465

263

264

https://t.me/med1917

Tong JC, Ren EC (2009) Immunoinformatics: current trends and future directions. Drug Discov

Today 14:684–689 Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L (1998) Axonal transection in the

lesions of multiple sclerosis. N Engl J Med 338:278–285 Uribe CF, Mathotaarachchi S, Gaudet V, Smith KC, Rosa-Neto P, Bénard F, Black SE, Zukotynski

K (2019) Machine learning in nuclear medicine: part 1—introduction. J Nucl Med 60:451–458 van Hamburg JP, Tas SW (2018) Molecular mechanisms underpinning T helper 17 cell heterogene-

ity and functions in rheumatoid arthritis. J Autoimmun 87:69–81 van Helden EJ, Vacher YJL, van Wieringen WN, van Velden FHP, Verheul HMW, Hoekstra OS,

Boellaard R, der Houven M-v, van Oordt CW (2018) Radiomics analysis of pre-treatment

[18F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative sys-

temic treatment. Eur J Nucl Med Mol Imaging 45:2307–2317 Venkatakrishnan AJ, Kayal N, Anand P, Badley AD, Church GM, Soundararajan V (2020)

Benchmarking evolutionary tinkering underlying human–viral molecular mimicry shows mul-

tiple host pulmonary–arterial peptides mimicked by SARS-CoV-2. Cell Death Discov 6:96 Vivona S, Bernante F, Filippini F (2006) NERVE: new enhanced reverse vaccinology environment.

BMC Biotechnol 6:35 Vojdani A (2014) A potential link between environmental triggers and autoimmunity. Autoimmune

Dis 2014:1–18 Wu H-J, Wu E (2012) The role of gut microbiota in immune homeostasis and autoimmunity. Gut

Microbes 3:4–14 Yadav SK, Mindur JE, Ito K, Dhib-Jalbut S (2015) Advances in the immunopathogenesis of mul-

tiple sclerosis. Curr Opin Neurol 28:206–219 Yasuma K, Yasunaga J, Takemoto K, Sugata K, Mitobe Y, Takenouchi N, Nakagawa M, Suzuki Y,

Matsuoka M (2016) HTLV-1 bZIP factor impairs anti-viral immunity by inducing co-inhibitory

molecule, T cell immunoglobulin and ITIM domain (TIGIT). PLoS Pathog 12:e1005372 Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo

VK (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat

Immunol 6:1245–1252 Zhu H, Luo H, Yan M, Zuo X, Li Q-Z (2015) Autoantigen microarray for high-throughput auto-

antibody proling in systemic lupus erythematosus. Genomics Proteomics Bioinformatics

13:210–218 Ziemssen T, De Stefano N, Sormani MP, Van Wijmeersch B, Wiendl H, Kieseier BC (2015)

Optimizing therapy early in multiple sclerosis: an evidence-based view. Mult Scler Relat

Disord 4:460–469

S. Gangwar et al.

Chapter 13

https://t.me/med1917

Erythropoietin intheTreatment ofAnaemia

NibirGhosh, GourabDey, PallabitaRakshit, andSouravDe

Abstract Anaemia is a prevalent clinical presentation in individuals suffering from

chronic kidney disease (CKD). This issue is linked to an elevated incidence of illness and death in patients. Erythropoietin is a renal hormone that is essential for the synthesis of red blood cells (RBCs). Anemia occurs due to a lack of production and premature destruction of RBC. The basic role of erythropoietin is to stimulate the bone marrow and increase the production of RBC when the body has a low oxygen level in the circulatory system. In anaemia, there is a deciency of RBC or haemoglobin. In this condition, the body may release more erythropoietin in response to low oxygen levels. If the anaemia is related to the production of RBC or CKD, erythropoietin therapy can be used. This therapy will stimulate the bone marrow to produce more RBC.The rst recombinant human erythropoietin was epoetin alpha approved by the US FDA in 1989. A substance similar to that of epoetin alpha is known as erythropoietin stimulating agent (EPA). Nowadays, treatment with ESA agents has become very popular for the treatment of anaemia that occurs in CKD patients. This chapter focuses on the role of ESA therapy in the treatment of anaemic patients with CKD.

Keywords Anaemia · Chronic kidney disease · Erythropoietin · ESA agent

N. Ghosh · G. Dey · S. De (*) Department of Pharmaceutical Technology, Eminent College of Pharmaceutical Technology, Kolkata, India

P. Rakshit Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India

Ltd. 2024 S. Bose et al. (eds.), Concepts in Pharmaceutical Biotechnology and Drug Development, Interdisciplinary Biotechnological Advances,

https://doi.org/10.1007/978-981-97-1148-2_13

266

https://t.me/med1917

N. Ghosh et al.

13.1 Introduction

A number of chronic illnesses, including chronic kidney disease (CKD), might have anaemia as a side effect. An absolute decline in the total quantity of red blood cells (RBCs) in circulation is referred to as anaemia. For clinical purposes, anaemia is diagnosed by considering factors like haemoglobin concentration, haematocrit, or RBC count. The existence of an illness or disease is indicated by this condition in the laboratory; anaemia by itself should not be regarded as a diagnosis (Barany 2007). Three aetiologic categories—increased RBC breakdown, decreased RBC generation, and blood loss—are typically utilised to classify anaemia. Anemia can also be associated with several chronic diseases, such as chronic kidney disease (CKD). Renal failure, which is caused by the loss of kidney function in whole or in part, poses a serious risk to human health (Eschbach etal.

1989). The term “renal anaemia” describes the range of conditions in which toxic

uremic plasma chemicals or erythropoietin-related compounds disrupt the metabolism of RBCs, resulting in anaemia. Chronic renal deciency, characterised by different levels of impaired kidney function, often leads to renal anaemia. The main chain of the 34,000 Da glycoprotein erythropoietin (EPO) contains 193 amino acids. About 90% of renal interstitial cells release EPO, a hormone-like material, whereas 10% of liver cells do the same. The kidney has a vital function in regulating the amount of EPO in the blood. Reduced EPO synthesis, subsequent hypoxia, and impaired blood ow might result from injury to the renal glomerular or tubular tissues. This, in turn, might trigger the creation of more EPOs, exacerbating the situation. Following its synthesis, EPO cannot be kept directly inside the body; rather, it promptly undergoes metabolic processing (Brugnara 2003). The regulation of serum EPO levels is primarily inuenced by the feedback mechanism involving red blood cell pressure and haemoglobin. Disruption of this control results in uctuating levels of EPO, causing a prolonged elevation in serum EPO levels, nally resulting in kidney injury (Collins etal.

2000). Erythropoietin therapy is also used in the therapy of various disease-

induced anaemia such as CHF and diabetes mellitus.

13 Erythropoietin intheTreatment ofAnaemia

https://t.me/med1917

267

13.2 Pathophysiology ofAnaemia inCKD Patients

Anaemia in CKD is caused by various factors. It has long been believed that the steady decline in endogenous erythropoietin (EPO) levels is the primary factor. Anaemia in CKD patients can be caused by various factors, including absolute iron inadequacy because of impaired iron absorption or blood losses, systemic inammation resulting from CKD and associated comorbidities, shortened red cell lifespan, decreased bone marrow response to EPO because of uremic toxins, inefcient utilisation of iron stores caused by elevated hepcidin levels, and deciencies in folic acid or vitamin B12 (KDIGO Anemia Working Group 2012).

13.3 Hypoxia-Induced Factor

EPO assembled in the bone marrow’s erythroid progenitor cells via attaching to their surface receptor is a glycoprotein with a molecular weight of 30.4kDa— primarily works as a primary stimulant for the differentiation, proliferation, and survival of red blood cells. The kidneys’ broblast-like interstitial peritubular cells and the liver’s perisinusoidal cells are the primary sources of EPO, which is generated in response to changes in tissue oxygen concentration (Pan etal.

2011; Rankin etal. 2009). Transcription of the EPO gene regulates the amount

of EPO produced. The hypoxia-inducible factor (HIF) system is an important regulator of its expression, as its activity is dependent upon the level of oxygen present in the tissue (Provenzano etal. 2016), (Fig.13.1).

268

https://t.me/med1917

N. Ghosh et al.

oxygen, FIH-1 factor inhibiting HIF, CBP CREB-binding protein, pVHL Von Hippel Lindau protein, HIF-PHI hypoxia-inducible factor

Fig. 13.1 The control of HIF at normal oxygen levels, the impact of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) on the body’s response

to low oxygen levels, and the regulation of HIF during low oxygen levels. Abbreviation: HIF hypoxia-inducible factor, OH hydroxyl, PHD prolyl hydroxylase

domain protein, O

prolyl hydroxylase inhibitor

<<< < Предыдущая 16 17 18 19 20 21 22 23 24 25 26 2728 / 4828 29 30 31 32 33 34 35 36 37 38 39 40 > Следующая >>>

Соседние файлы в папке Библиотека им академика М.И. Перельмана

#
29.08.202686 Мб0Книга_539_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202616 Мб0Книга_5390_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202615 Мб0Книга_5394_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202615 Мб0Книга_5395_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202615 Мб0Книга_5396_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202615 Мб15Книга_5397_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202615 Мб0Книга_5398_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202615 Мб0Книга_5399_Библиотеки_им_академика_М_И_Перельмана.pdf
#
29.08.202686 Мб0Книга_540_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202615 Мб0Книга_5400_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202614 Мб0Книга_5401_Библиотеки_им_академика_М_И_Перельмана.pdf